Clinical Trial: A Prospective, Open-Label, Multicenter Clinical Study of Intravenous Disitamab Vedotin Combined with Intravesical Gemcitabine for HER2-Expressing High-Risk Non-Muscle Invasive Bladder Cancer. (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Open-Label, Multicenter Clinical Study of Intravenous Disitamab Vedotin Combined with Intravesical Gemcitabine for HER2-Expressing High-Risk Non-Muscle Invasive Bladder Cancer.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131822

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: Lishui Central Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=325063

Published by HT Digital Content Services with permission from Health Daily Digest....